In an announcement on October 7, Danaher Corporation said it will build its first AI-powered autonomous laboratory, intended to design, build, and test custom antibodies with minimal human intervention, with full operating capacity targeted for early 2027.

Danaher supplies a range of instruments and reagents to drug developers and academic researchers. Antibodies and other affinity reagents are foundational tools across biomedical research, and producing them has traditionally involved slow, iterative manual experimentation. The company expects that automating the most time-consuming areas of early-stage discovery will give it a commercial edge.

The lab will be based at Abcam, one of Danaher's operating companies, and will combine AI, robotics, and tools from across the group in a single workflow. The system will use AI to design new affinity reagents, including antibodies, before robots build and test the candidates. Results will then feed back into the model, allowing each new round of designs to improve on the last, according to Danaher's announcement. company refers to this as a continuous “design-make-test-learn” loop. That closed-loop setup mirrors the “self-driving lab” model gaining traction across the life sciences industry, as instrument makers and drug developers turn to automation to raise experimental throughput.

Five Danaher units will supply the underlying technology: Beckman Coulter Life Sciences, Cytiva, Genedata, Integrated DNA Technologies, and Molecular Devices. Robotic automation and device orchestration will be delivered through work with Automata, a company Danaher invested in back in January 2026, according to Quartz.

Eight times faster, with ten times more output

According to the company's press release, the lab is expected to speed up affinity reagent discovery by up to eight times and eventually increase annual reagent output by nearly ten times, moving from tens to hundreds of reagents annually as it scales over time.

JC Gutierrez-Ramos, Danaher's senior vice president and chief science officer, said the lab represents a new way of doing scientific research, combining AI and automation with human expertise in a continuous cycle. He added that scientists will still make the key decisions, while the autonomous platform handles the repetitive experimental work.

Chief Executive Officer Julie Sawyer Montgomery described the project as an early step rather than a finished system. She said it could help usher in a future where AI, automation, and intelligent systems contribute significantly to accelerating the path from scientific discovery to real-world impact.

One lab within a larger plan

The Abcam facility is expected to be the first step in an ongoing effort to build what the company calls a fleet of smart instruments. These devices are designed to be easier to control through software, generate data that is ready for AI use, and run “expert-level” agentic systems.

Per the announcement, instruments in use at the facility could eventually be connected across additional autonomous labs, allowing the same self-improving cycle to run across different research programs. Progress toward the early-2027 capacity target, and whether the fleet concept extends to further connected labs, will show how quickly Danaher can turn the design-make-test-learn model from a single-site pilot into broader research infrastructure.

Danaher shares rose about 2% in premarket trading on Wednesday, according to Yahoo Finance data. Before the announcement, Barclays analyst Luke Sergott had raised his price target for Danaher to $255 from $230 while keeping an Overweight rating on the stock.

Danaher shares were trading at around $219 as of the time of writing.